Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory

Catheterization and Cardiovascular Interventions

Volumn 65, Issue 3, 2005, Pages 330-337

  Doherty, Terence M ^a   Shavelle, Robert M ^b   French, William J ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Life Expectancy Project   (United States)

Author keywords

Activated partial thromboplastin time; Anticoagulation; Heparin; Prothrombin time; Whole blood activated coagulation time

Indexed keywords

PROTHROMBIN; THROMBOPLASTIN;

ACTIVATED CLOTTING TIME; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART CATHETERIZATION; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REPRODUCIBILITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG MONITORING; FEMALE; HEART CATHETERIZATION; HEPARIN; HUMANS; INTRAOPERATIVE PERIOD; LABORATORIES; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; THROMBOSIS; WHOLE BLOOD COAGULATION TIME;

EID: 21244454062     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20355     Document Type: Article

References (36)

1. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436-440.
2. Hattersley PG. Progress report: the activated coagulation time of whole blood (ACT). Am J Clin Pathol 1976;66:899-904.
3. Hattersley PG, Mitsuoka JC, King JH. Sources of error in heparin therapy of thromboembolic disease. Arch Intern Med 1980;140:1173-1175.
4. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation: II, the use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975;69:685-689.
5. Despotis GJ, Alsoufiev AL, Spitznagel E, Goodnough LT, Lappas DG. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses. Ann. Thorac Surg 1996;61:795-799.
6. Brener SJ, Bhatt DL, Moliterno DJ, Schneider JP, Ellis SG, Topol EJ. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Am J Cardiol 2003;92:1468-1471.
7. Kulick DL, Kawanishi DT. Percutaneous transluminal coronary angioplasty. In: Kulick DL, Rahimtoola SH, editors. Techniques and applications in interventional cardiology. St.Louis, MO: Mosby Year Book; 1991. p 43-118.
8. Gablini G, Deligonul U, Kern MJ, Vandormael M. Acute coronary occlusion occurring after successful percutaneous transluminal coronary angioplasty: temporal relationship to discontinuation of anticoagulation. Am Heart J 1988;116:696-700.
9. Dougherty KG, Marsh KC, Edelman SK, Gaos CM, Ferguson JJ, Leachman DR. Relationship between procedural activated clotting time and in-hospital post-PTCA outcome. Circulation 1990;82(Suppl 3)III189.
10. Harrington RA, Leimberger JD, Berdan LG, Topol EJ, Califf RM. The ACT index: a method for stratifying likelihood of success and risk of acute complications in coronary intervention. Circulation 1993;88(Suppl 1):1208.
11. Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
12. Hillegass WB, Brott BC, Chapman GD, Phillips HR, Stack RS, Tcheng JE, Califf RM. Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. AM Heart J 2002;144:501-507.
13. Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, Sapp SK, Cabot CF, Tcheng JE, Califf RM, Effron MB, Topol EJ. Abiximab and bleeding during coronary surgery: results from the EPLOG and EPISTENT trials. Ann Thorac Surg 2000;70:516-526.
14. Avendano A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:907-910.
15. Ferguson JJ. Hemochron versus HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1995;25:803-804.
16. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn 1989;18:206-209.
17. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc, Diagn 1992;26:260-263.
18. Zahn R, Haubelt H, Bechtloff S, Schneider S, Frilling B, Rustige J, Marsalek P, Seidl K, Senges J, Hellstern P. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Herz 2003;28:445-452.
19. Dangas G, Marmur JD, King TE, De Leon J, Sharma SK, Vidhun R, Feldman D, Stoynov MY, Badimon JJ, Ambrose JA. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J 1999;138:49-54.
20. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician 1983;32:307-317.
21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
22. Bookbinder MJ, Pansian KJ. Using the coefficient of correlation in method-comparison studies. Clin Chem 1987;33:1170-1176.
23. Aylsworth CL, Stefan F, Woitas K, Rieger RH, LeBoutillier M, III, DiSesa VJ. New technology, old standards: disparate activated clotting time measurements by the Hemochron Jr compared with the standard Hemochron. Ann Thorac Surg 2004;77:973-976.
24. Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. Variability of the activated coagulation time. Anesth Analg 1988;67:469-472.
25. Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M, Franco I. Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn 1993;28:279-282.
26. Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revasculaization: PROLOG investigators. Am J Cardiol 1997;79:286-291.
27. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. AM J Cardiol 1998;81:36-40.
28. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention: EPIC investigators. Circulation 1995;91:2882-2890.
29. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol 1995;75:559-562.
30. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-617.
31. Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am j Cardiol 1998;82:50P-56P.
32. Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G, Harrington RA, Tcheng JE. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. Am Coll Cardiol 2003;41:386-393.
33. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-966.
34. Franke JG, Mildenberger RR, Mackenzie GW, Morch JE, Williams MB, Brownlee RT, Kemna GD. Heparin requirements in coronary angioplasty. Ann NY Acad Sci 1989;556:447-449.
35. Levy JH, Kelley A. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time. Circulation 1997;96:3793-3794.
36. Wilson JM, Dougherty KG, Elis KO, Ferguson JJ. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1995;34:1-5.